Skip to search formSkip to main contentSkip to account menu

AR-12286

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Isoquinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% Efficacy in Patients with Exfoliation Syndrome (XFS) and Ocular Hypertension (OHT) or Exfoliative Glaucoma (XFG)
Highly Cited
2014
Highly Cited
2014
Emerging trabecular outflow drugs.
Glaucoma is a progressive optic neuropathy that is a leading cause of irreversible blindness worldwide.1 Elevated intraocular… 
2013
2013
Ocular hypotensive efficacy and safety of a fixed dose combination of AR-12286 (a Rho Kinase Inhibitor) and travoprost
2011
2011
Ocular Hypotensive Efficacy, Safety, and Systemic Absorption of AR-12286 in Normal Volunteers
2011
2011
A 28-day active-controlled, Phase 2b study assessing the safety and ocular hypotensive efficacy of AR-12286 in patients with elevated intraocular pressure
2010
2010
Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 2.
  • L. Hookes
  • IDrugs : the investigational drugs journal
  • 2010
  • Corpus ID: 26693573
The 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Fort Lauderdale, FL, USA… 
2010
2010
Ocular Hypotensive Efficacy and Safety of the Rho Kinase Inhibitor AR-12286 in Patients With Elevated Intraocular Pressure
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)